Market Place
Sourcing Support
SpringWorks Reports Data on OGSIVEO in Desmoid Tumors at CTOS 2024
07 Nov 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Reports Q2 2024 Results And Business Highlights
07 Aug 2024 //
GLOBENEWSWIRE
GSK axes Blenrep combo studies with SpringWorks` Ogsiveo
11 Jun 2024 //
FIERCE PHARMA
SpringWorks Q1 2024 Results, Business Updates
02 May 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Announces EMA Validation for MAA of Nirogacestat
29 Feb 2024 //
GLOBENEWSWIRE
SpringWorks Announces EMA Validation for MAA of Nirogacestat
29 Feb 2024 //
PRESS RELEASE
OGSIVEO Available from Onco360 as First and Only Treatment for Desmoid Tumors
30 Nov 2023 //
BUSINESSWIRE
SpringWorks` non-cancerous tumor drug to be priced at $29,000 per month in US
28 Nov 2023 //
REUTERS
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
28 Nov 2023 //
FDA
SpringWorks Announces Presentation of Data from Phase 3 Trial of Nirogacestat
01 Nov 2023 //
GLOBENEWSWIRE
SpringWorks Announces Presentation of Data from PIII DeFi Trial of Nirogacestat
25 May 2023 //
GLOBENEWSWIRE
SpringWorks Announces Presentations of Nirogacestat with BCMA-Directed Therapies
11 May 2023 //
GLOBENEWSWIRE
SpringWorks Announces Publication of Phase 3 DeFi Trial Evaluating Nirogacestat
08 Mar 2023 //
PRESS RELEASE
Pfizer spinout SpringWorks gets FDA priority review for lead drug
28 Feb 2023 //
ENDPTS
SpringWorks completes submission of NDA to US FDA for nirogacestat
29 Dec 2022 //
PHARMABIZ
SpringWorks Completes Submission of NDA to the FDA for Nirogacestat
28 Dec 2022 //
BIOSPACE
SpringWorks Announces Dosing of First Patient in Phase 2 Trial Nirogacestat
29 Sep 2022 //
GLOBENEWSWIRE
Novel Nirogacestat Shows Significant Efficacy in the Treatment of Progressing
14 Sep 2022 //
FIRSTWORLDPHARMA
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Nirogacestat
10 Sep 2022 //
GLOBENEWSWIRE
SpringWorks Announces Expansion of Global, Collaboration GSK for Nirogacestat
07 Sep 2022 //
GLOBENEWSWIRE
SpringWorks Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data
19 Aug 2022 //
GLOBENEWSWIRE
SpringWorks` stock jumps as phase 3 tumor trial hits goal
25 May 2022 //
FIERCEBIOTECH
SpringWorks Announces CT Collaboration and Supply Agreement with Regeneron
19 Apr 2022 //
GLOBENEWSWIRE
SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie
10 Dec 2021 //
GLOBENEWSWIRE
SpringWorks Begins Dosing in Phase 1b/2 Trial for Nirogacestat + Elranatamab
06 Dec 2021 //
PRESS RELEASE
SpringWorks & Leading Cancer Institute collaborate to Evaluate Nirogacestat
30 Aug 2021 //
GLOBENEWSWIRE
Allogene Receives IND Clearance from the U.S. FDA for ALLO-715
23 Dec 2020 //
ALLOGENE
Allogene Receives IND Clearance from the U.S. FDA for ALLO-715
23 Dec 2020 //
PRESS RELEASE
Precision &SpringWorks Announce Collaboration to Evaluate PBCAR269A+Nirogacestat
21 Sep 2020 //
GLOBENEWSWIRE
